Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04522830Phase 2Completed

A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19

Role: lead

NCT01902303Phase 2Completed

Evaluation of Cold Sore Treatments on Ultra Violet (UV) Induced Cold Sores

Role: lead

NCT01308424Phase 1Completed

Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection

Role: lead

NCT01340066Phase 1Completed

Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence

Role: lead

All 4 trials loaded